Aptose Biosciences Inc. (APS.TO)
CAD 0.27
(0.0%)
CAD 0.27
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 15.89 Million USD | 19.6% |
| 2022 | 13.28 Million USD | 60.28% |
| 2021 | 8.28 Million USD | 12.82% |
| 2020 | 7.34 Million USD | 12.17% |
| 2019 | 6.55 Million USD | 134.85% |
| 2018 | 2.78 Million USD | 58.02% |
| 2017 | 1.76 Million USD | 34.03% |
| 2016 | 1.31 Million USD | -22.44% |
| 2015 | 1.69 Million USD | -15.54% |
| 2014 | 2.01 Million USD | -11.33% |
| 2013 | 2.26 Million USD | 28.67% |
| 2012 | 1.76 Million USD | -32.65% |
| 2011 | 2.61 Million USD | 120.51% |
| 2010 | 1.18 Million USD | -56.0% |
| 2009 | 2.69 Million USD | -81.49% |
| 2008 | 14.56 Million USD | -6.31% |
| 2007 | 15.54 Million USD | 13.0% |
| 2006 | 13.75 Million USD | 8.07% |
| 2005 | 12.73 Million USD | 11.71% |
| 2004 | 11.39 Million USD | 166.57% |
| 2003 | 4.27 Million USD | 9.46% |
| 2002 | 3.9 Million USD | 73.94% |
| 2001 | 2.24 Million USD | -41.13% |
| 2000 | 3.81 Million USD | 58.39% |
| 1999 | 2.4 Million USD | 173.12% |
| 1998 | 881.66 Thousand USD | 16.75% |
| 1997 | 755.18 Thousand USD | -5.38% |
| 1996 | 798.14 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 12.65 Million USD | -20.33% |
| 2024 Q2 | 13.12 Million USD | 3.68% |
| 2023 Q3 | 13.1 Million USD | 2.43% |
| 2023 Q1 | 13.33 Million USD | 0.38% |
| 2023 Q2 | 12.78 Million USD | -4.11% |
| 2023 Q4 | 15.89 Million USD | 21.3% |
| 2023 FY | 15.89 Million USD | 19.6% |
| 2022 Q2 | 9.31 Million USD | 27.27% |
| 2022 Q1 | 7.31 Million USD | -11.7% |
| 2022 Q3 | 10.23 Million USD | 9.87% |
| 2022 Q4 | 13.28 Million USD | 29.82% |
| 2022 FY | 13.28 Million USD | 60.28% |
| 2021 Q2 | 8.02 Million USD | 38.64% |
| 2021 Q3 | 8.51 Million USD | 6.13% |
| 2021 Q4 | 8.28 Million USD | -2.69% |
| 2021 FY | 8.28 Million USD | 12.82% |
| 2021 Q1 | 5.78 Million USD | -21.21% |
| 2020 Q4 | 7.34 Million USD | 20.4% |
| 2020 Q3 | 6.1 Million USD | 0.05% |
| 2020 Q2 | 6.09 Million USD | 14.64% |
| 2020 Q1 | 5.32 Million USD | -18.78% |
| 2020 FY | 7.34 Million USD | 12.17% |
| 2019 Q3 | 5.03 Million USD | 13.49% |
| 2019 Q1 | 4.29 Million USD | 54.14% |
| 2019 Q4 | 6.55 Million USD | 30.17% |
| 2019 FY | 6.55 Million USD | 134.85% |
| 2019 Q2 | 4.43 Million USD | 3.14% |
| 2018 Q4 | 2.78 Million USD | 17.68% |
| 2018 Q2 | 2.4 Million USD | 8.89% |
| 2018 FY | 2.78 Million USD | 58.02% |
| 2018 Q1 | 2.2 Million USD | 24.93% |
| 2018 Q3 | 2.37 Million USD | -1.29% |
| 2017 Q4 | 1.76 Million USD | 32.22% |
| 2017 Q3 | 1.33 Million USD | 32.73% |
| 2017 Q2 | 1 Million USD | -42.68% |
| 2017 Q1 | 1.75 Million USD | 33.25% |
| 2017 FY | 1.76 Million USD | 34.03% |
| 2016 Q4 | 1.31 Million USD | -15.09% |
| 2016 Q1 | 1.43 Million USD | -15.74% |
| 2016 Q2 | 1.39 Million USD | -2.7% |
| 2016 FY | 1.31 Million USD | -22.44% |
| 2016 Q3 | 1.55 Million USD | 11.41% |
| 2015 Q4 | 1.69 Million USD | 33.92% |
| 2015 FY | 1.69 Million USD | -15.54% |
| 2015 Q1 | 2.17 Million USD | 108273.91% |
| 2015 Q2 | 1.23 Million USD | -43.24% |
| 2015 Q3 | 1.26 Million USD | 2.52% |
| 2014 Q2 | 2.26 Million USD | -31.77% |
| 2014 Q4 | 2010.24 USD | -99.88% |
| 2014 Q1 | 3.32 Million USD | -7.87% |
| 2014 FY | 2.01 Million USD | -11.33% |
| 2014 Q3 | 1.65 Million USD | -26.93% |
| 2013 Q3 | 2.56 Million USD | 45.36% |
| 2013 Q4 | 3.6 Million USD | 40.82% |
| 2013 Q1 | 1.39 Million USD | -12.22% |
| 2013 Q2 | 1.76 Million USD | 25.88% |
| 2013 FY | 2.26 Million USD | 28.67% |
| 2012 Q3 | 1.5 Million USD | -42.34% |
| 2012 Q1 | 1.58 Million USD | 12.41% |
| 2012 Q4 | 1.59 Million USD | 5.71% |
| 2012 FY | 1.76 Million USD | -32.65% |
| 2012 Q2 | 2.61 Million USD | 64.94% |
| 2011 Q3 | 1.23 Million USD | 4.0% |
| 2011 FY | 2.61 Million USD | 120.51% |
| 2011 Q4 | 1.41 Million USD | 14.35% |
| 2011 Q2 | 1.18 Million USD | 3.98% |
| 2011 Q1 | 1.14 Million USD | -33.29% |
| 2010 Q1 | 1.36 Million USD | -27.8% |
| 2010 Q2 | 2.69 Million USD | 98.19% |
| 2010 Q4 | 1.71 Million USD | -46.22% |
| 2010 Q3 | 3.18 Million USD | 17.97% |
| 2010 FY | 1.18 Million USD | -56.0% |
| 2009 Q2 | 14.56 Million USD | 19.11% |
| 2009 Q3 | 1.45 Million USD | -89.98% |
| 2009 Q4 | 1.88 Million USD | 29.07% |
| 2009 FY | 2.69 Million USD | -81.49% |
| 2009 Q1 | 12.23 Million USD | -0.57% |
| 2008 Q3 | 14.59 Million USD | -6.15% |
| 2008 FY | 14.56 Million USD | -6.31% |
| 2008 Q4 | 12.3 Million USD | -15.7% |
| 2008 Q1 | 15.2 Million USD | 6.76% |
| 2008 Q2 | 15.54 Million USD | 2.25% |
| 2007 FY | 15.54 Million USD | 13.0% |
| 2007 Q1 | 11.68 Million USD | -5.27% |
| 2007 Q3 | 13.59 Million USD | -1.15% |
| 2007 Q4 | 14.24 Million USD | 4.73% |
| 2007 Q2 | 13.75 Million USD | 17.76% |
| 2006 Q4 | 12.33 Million USD | -4.43% |
| 2006 Q3 | 12.9 Million USD | 1.37% |
| 2006 Q2 | 12.73 Million USD | 3.48% |
| 2006 FY | 13.75 Million USD | 8.07% |
| 2006 Q1 | 12.3 Million USD | -6.37% |
| 2005 Q4 | 13.13 Million USD | 8.17% |
| 2005 Q3 | 12.14 Million USD | 6.6% |
| 2005 Q2 | 11.39 Million USD | 26.53% |
| 2005 Q1 | 9 Million USD | 36.26% |
| 2005 FY | 12.73 Million USD | 11.71% |
| 2004 FY | 11.39 Million USD | 166.57% |
| 2004 Q3 | 4.27 Million USD | 0.01% |
| 2004 Q2 | 4.27 Million USD | -26.19% |
| 2004 Q1 | 5.79 Million USD | 25.44% |
| 2004 Q4 | 6.61 Million USD | 54.6% |
| 2003 Q1 | 2.81 Million USD | -10.05% |
| 2003 FY | 4.27 Million USD | 9.46% |
| 2003 Q4 | 4.61 Million USD | -7.46% |
| 2003 Q3 | 4.98 Million USD | 27.76% |
| 2003 Q2 | 3.9 Million USD | 38.52% |
| 2002 Q4 | 3.13 Million USD | 14.37% |
| 2002 Q1 | 2.17 Million USD | 6.28% |
| 2002 FY | 3.9 Million USD | 73.94% |
| 2002 Q2 | 2.24 Million USD | 3.45% |
| 2002 Q3 | 2.74 Million USD | 22.06% |
| 2001 Q4 | 2.04 Million USD | -36.3% |
| 2001 FY | 2.24 Million USD | -41.13% |
| 2001 Q1 | 1.48 Million USD | -25.33% |
| 2001 Q2 | 3.81 Million USD | 157.38% |
| 2001 Q3 | 3.2 Million USD | -15.94% |
| 2000 Q4 | 1.98 Million USD | 39.66% |
| 2000 Q2 | 2.4 Million USD | 168.78% |
| 2000 Q3 | 1.42 Million USD | -40.99% |
| 2000 Q1 | 895.89 Thousand USD | -51.14% |
| 2000 FY | 3.81 Million USD | 58.39% |
| 1999 Q1 | 795.49 Thousand USD | 35.76% |
| 1999 Q3 | 1.07 Million USD | 21.43% |
| 1999 FY | 2.4 Million USD | 173.12% |
| 1999 Q4 | 1.83 Million USD | 71.27% |
| 1999 Q2 | 881.66 Thousand USD | 10.83% |
| 1998 FY | 881.66 Thousand USD | 16.75% |
| 1998 Q4 | 585.93 Thousand USD | -7.4% |
| 1998 Q1 | 491.84 Thousand USD | -41.67% |
| 1998 Q2 | 755.18 Thousand USD | 53.54% |
| 1998 Q3 | 632.75 Thousand USD | -16.21% |
| 1997 Q3 | 503.95 Thousand USD | 0.0% |
| 1997 FY | 755.18 Thousand USD | -5.38% |
| 1997 Q4 | 843.28 Thousand USD | 67.33% |
| 1996 FY | 798.14 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Appili Therapeutics Inc. | 12.41 Million CAD | -27.988% |
| Eupraxia Pharmaceuticals Inc. | 25.54 Million CAD | 37.8% |
| Helix BioPharma Corp. | 1.57 Million CAD | -906.333% |
| Microbix Biosystems Inc. | 11.02 Million CAD | -44.081% |
| Medicenna Therapeutics Corp. | 13.94 Million CAD | -13.964% |
| Satellos Bioscience Inc. | 3.62 Million CAD | -338.466% |
| Oncolytics Biotech Inc. | 11.25 Million CAD | -41.157% |
| Sernova Corp. | 9.59 Million CAD | -65.654% |